Latest Breaking News On - Biocryst pharmaceuticals inc - Page 2 : comparemela.com

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) CFO Anthony Doyle bought 36,300 shares of the stock in a transaction on Tuesday, May 14th. The stock was purchased at an average cost of $5.57 per share, for a total transaction of $202,191.00. Following the acquisition, the chief financial officer now owns 266,744 shares of the […]

Anthony doyleFifth third bancorpNeedham companySecurities exchange commissionThird bancorpNews ratings for biocryst pharmaceuticals dailyInstitutional investors weigh in on biocryst pharmaceuticalsBiocryst pharmaceuticals incBiocryst pharmaceuticals stock performanceChina universal asset management coBiocryst pharmaceuticalsGet free reportExchange commissionCryst pharmaceuticalsUniversal asset managementEight capital